Common Contracts
9 similar Investors’ Rights Agreement contracts by Codex DNA, Inc., Flex Pharma, Inc., Applovin Corp, others
SEQUOIA VACCINES, INC. 2021 INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • November 6th, 2023 • Sequoia Vaccines, Inc. • Biological products, (no disgnostic substances) • Missouri
THIS 2021 INVESTORS’ RIGHTS AGREEMENT (“Agreement”) is made as of ____April 30__, 2021 by and among Sequoia Vaccines, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A (each of which is referred to in this Agreement as an “Investor”), and any additional investor that becomes a party to this Agreement in accordance with Section 6.9 hereof. This Agreement supersedes and replaces in its entirety that 2020 Amended and Restated Investors’ Rights Agreement dated April 6, 2020 by and among the Company and the other parties thereto.
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • August 6th, 2021 • Entrada Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made and entered into as of this 29th day of March, 2021, by and among Entrada Therapeutics, Inc. (f/k/a CycloPorters, Inc.), a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and each of the entities listed on Schedule B hereto, each of which is referred to in this Agreement as a “Licensor Stockholder.”
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • May 28th, 2021 • Codex DNA, Inc. • Laboratory analytical instruments • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 19th day of December, 2019, by and among SGI-DNA, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.9 hereof.
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • March 16th, 2021 • Codex DNA, Inc. • Laboratory analytical instruments • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 19th day of December, 2019, by and among SGI-DNA, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.9 hereof.
M&M Media, Inc. d/b/a/ Trebel Investors’ Rights Agreement December 18, 2017 INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • February 12th, 2021 • M&m Media, Inc. • Connecticut
This Investors’ Rights Agreement (this “Agreement”) is made as of December 18, 2017 by and among M&M Media, Inc., d/b/a/ Trebel, a Delaware corporation (the “Company”) and each Investor (as defined below).
APPLOVIN CORPORATION INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • December 7th, 2020 • Applovin Corp • Services-computer programming, data processing, etc. • Delaware
This Investors’ Rights Agreement (this “Agreement”) is made and entered into as of August 15, 2018 by and among Applovin Corporation, a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” each of the stockholders listed on Schedule B hereto, each of whom is referred to herein as a “Key Holder,” and any holder of a Lender Warrant that becomes a party to this Agreement in accordance with Section 7.14 hereof.
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • January 24th, 2020 • Lantern Pharma Inc. • Pharmaceutical preparations • Texas
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as March 17, 2017, by and among Lantern Pharma Inc., a Texas corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, and each of the stockholders listed on Schedule B hereto, each of whom is referred to herein as a “Key Holder” and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.8 hereof.
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • December 29th, 2014 • Flex Pharma, Inc. • Pharmaceutical preparations • Delaware
This AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT is made as of the 23rd day of July, 2014, by and among FLEX PHARMA, INC., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.9 hereof, and the stockholders listed on Schedule B hereto, each of whom is referred to as a “Key Holder”.
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • October 29th, 2014 • Flex Pharma, Inc. • Pharmaceutical preparations • Delaware
This AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT is made as of the 23rd day of July, 2014, by and among FLEX PHARMA, INC., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.9 hereof, and the stockholders listed on Schedule B hereto, each of whom is referred to as a “Key Holder”.
